| 1 |
34912339 | Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia. | 2021 |
3 |
| 2 |
31871305 | Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. | 2020 Mar |
4 |
| 3 |
29869556 | A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. | 2018 Sep |
1 |
| 4 |
30030853 | The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC). | 2018 Jul 20 |
2 |
| 5 |
29296914 | Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. | 2017 Dec 12 |
1 |
| 6 |
25767114 | Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets. | 2015 May 1 |
1 |